Intradermal vaccination using the novel microneedle device MicronJet600: Past, present, and future.
Intradermal immunization has become a forefront of vaccine improvement, both scientifically and commercially. Newer technologies are being developed to address the need to reduce the dose required for vaccination and to improve the reliability and ease of injection, which have been major hurdles in expanding the number of approved vaccines using this route of administration. In this review, 7 y of clinical experience with a novel intradermal delivery device, the MicronJet600, which is a registered hollow microneedle that simplifies the delivery of liquid vaccines, are summarized. This device has demonstrated both significant dose-sparing and superior immunogenicity in various vaccine categories, as well as in diverse subject populations and age groups. These studies have shown that intradermal delivery using this device is safe, effective, and preferred by the subjects. Comparison with other intradermal devices and potential new applications for intradermal delivery that could be pursued in the future are also discussed.
|Journal||Human Vaccines and Immunotherapeutics|
|Publisher||Taylor and Francis|
|Disease||, Diphtheria , Human papillomavirus , immunogenicity , influenza vaccine , Pertussis , Poliomyelitis , Tetanus , vaccine delivery|
|Added by||Marilyn Kelly|
|Added on||9 March 2017 15:59:35|
Add to Favourites